Galenus Prize 2025: Elahere wins in the Specialist Care category
AbbVie's mirvetuximab soravtansine ( Elahere® ) is the first treatment for platinum-resistant, high-grade serous ovarian cancer (OCa) to be associated with a clinically meaningful improvement in overall survival compared to investigator-choice chemotherapy in a phase III trial. The drug won the Galenus of Pergamon Award in the Specialist Care category.
Arzte zeitung
